Yoichiro Tsukada1,2,3, Takahiro Higashi4, Hideaki Shimada5, Yoshinori Kikuchi6, Atsuro Terahara7. 1. Division of Health Services Research, Center for Cancer Control and Information Services, National Cancer Center, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. yotsukad@ncc.go.jp. 2. Department of Radiology, Toho University Omori Medical Center, Tokyo, Japan. yotsukad@ncc.go.jp. 3. Department of Clinical Oncology, Toho University Graduate School of Medicine, Tokyo, Japan. yotsukad@ncc.go.jp. 4. Division of Health Services Research, Center for Cancer Control and Information Services, National Cancer Center, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. 5. Department of Surgery, Faculty of Medicine, Toho University, Tokyo, Japan. 6. Division of Gastorenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine, Toho University, Tokyo, Japan. 7. Department of Radiology, Toho University Omori Medical Center, Tokyo, Japan.
Abstract
BACKGROUND: Recent studies have shown the benefits of neoadjuvant therapy with chemotherapy or chemoradiotherapy for resectable locally advanced thoracic esophageal squamous cell carcinoma (ESCC). The aim of our study was to elucidate the use of neoadjuvant therapy for thoracic ESCC in Japan. METHODS: Data on patients with stage IB-III thoracic ESCC were retrieved from the national database of hospital-based cancer registries combined with claims data between 2012 and 2013. These data were analyzed using a mixed-effect logistic regression analysis, with a focus on exploring patterns in the first-line treatment for ESCC, including proportion of patients who received neoadjuvant therapy, and investigating the hospital characteristics and patient factors associated with the use of neoadjuvant therapy. RESULTS: Of the 5016 patients with stage IB-III thoracic ESCC at the 305 participating hospitals, 34.2% received neoadjuvant therapy (neoadjuvant chemotherapy, 29.5%; neoadjuvant chemoradiotherapy, 4.7%). The therapy was less likely to be administered to older patients (≤64 years, 48.8%; 65-70 years, 42.0%; 70-75 years, 33.9%; 75-80 years, 22.2%; 80-85 years, 3.8%; ≥85 years, 1.4%) and at hospitals with a low volume of patients (very high, 42.1%; high, 37.5%; low, 30.7%; and very low, 26.4%). This trend was confirmed by regression analysis. CONCLUSIONS: Based on our results, in Japan, relatively few patients with resectable locally advanced thoracic ESCC receive neoadjuvant therapy, with older patients and patients at lower volume hospitals being less likely than other patients to receive the neoadjuvant therapy. We recommend that the process of treatment decision-making be assessed at both the patient and hospital levels so that patients can consider various treatment options, including neoadjuvant therapy with surgery in Japan.
BACKGROUND: Recent studies have shown the benefits of neoadjuvant therapy with chemotherapy or chemoradiotherapy for resectable locally advanced thoracic esophageal squamous cell carcinoma (ESCC). The aim of our study was to elucidate the use of neoadjuvant therapy for thoracic ESCC in Japan. METHODS: Data on patients with stage IB-III thoracic ESCC were retrieved from the national database of hospital-based cancer registries combined with claims data between 2012 and 2013. These data were analyzed using a mixed-effect logistic regression analysis, with a focus on exploring patterns in the first-line treatment for ESCC, including proportion of patients who received neoadjuvant therapy, and investigating the hospital characteristics and patient factors associated with the use of neoadjuvant therapy. RESULTS: Of the 5016 patients with stage IB-III thoracic ESCC at the 305 participating hospitals, 34.2% received neoadjuvant therapy (neoadjuvant chemotherapy, 29.5%; neoadjuvant chemoradiotherapy, 4.7%). The therapy was less likely to be administered to older patients (≤64 years, 48.8%; 65-70 years, 42.0%; 70-75 years, 33.9%; 75-80 years, 22.2%; 80-85 years, 3.8%; ≥85 years, 1.4%) and at hospitals with a low volume of patients (very high, 42.1%; high, 37.5%; low, 30.7%; and very low, 26.4%). This trend was confirmed by regression analysis. CONCLUSIONS: Based on our results, in Japan, relatively few patients with resectable locally advanced thoracic ESCC receive neoadjuvant therapy, with older patients and patients at lower volume hospitals being less likely than other patients to receive the neoadjuvant therapy. We recommend that the process of treatment decision-making be assessed at both the patient and hospital levels so that patients can consider various treatment options, including neoadjuvant therapy with surgery in Japan.
Authors: Mohan Suntharalingam; Jennifer Moughan; Lawrence R Coia; Mark J Krasna; Lisa Kachnic; Daniel G Haller; Christopher G Willet; Madhu J John; Bruce D Minsky; Jean B Owen Journal: J Clin Oncol Date: 2005-04-01 Impact factor: 44.544
Authors: Shannon E Fogh; Anthony Yu; Gregory J Kubicek; Walter Scott; Edith Mitchell; Ernest L Rosato; Adam C Berger Journal: Int J Radiat Oncol Biol Phys Date: 2010-11-23 Impact factor: 7.038
Authors: Grace L Smith; Benjamin D Smith; Thomas A Buchholz; Zhongxing Liao; Melenda Jeter; Stephen G Swisher; Wayne L Hofstetter; Jaffer A Ajani; Mary F McAleer; Ritsuko Komaki; James D Cox Journal: Int J Radiat Oncol Biol Phys Date: 2009-03-14 Impact factor: 7.038
Authors: Aruna Munasinghe; Sheraz R Markar; Ravikrishna Mamidanna; Ara W Darzi; Omar D Faiz; George B Hanna; Donald E Low Journal: Ann Surg Date: 2015-07 Impact factor: 12.969